Insights
Search Results
Client Highlights
10.28.26
Wilson Sonsini Advises Orbus Therapeutics on IP Matters Related to Acquisition by US WorldMeds
On October 27, 2026, US WorldMeds, a specialty pharmaceutical company, and Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors, announced a definitive merger agreement under which US WorldMeds has acquired Orbus. Wilson Sonsini Goodrich & Rosati advised Orbus on IP matters in connection with the transaction.
Client Highlights
8.11.26
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
1.09.25
Wilson Sonsini Advises General Atlantic on IP Matters Related to Verdiva Bio’s Formation and $410 Million Series A
On January 9, 2025, Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. Verdiva launched with an oversubscribed Series A financing of $411 million, co-led by General Atlantic and Forbion, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital (collectively, “the Investor Group”). Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to Verdiva’s formation and Series A funding round.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.